Drug Trial Radar · NCT06263270
Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The Knee
Last checked: Nov 20, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Jun 1, 2024
Primary completion
Mar 15, 2025
Study completion Oct 10, 2025
Sponsor
- Lead sponsor
- Cytonics CorporationIndustry
- Sponsor type
- Industry
- First posted
- Feb 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Phase 1 study is to investigate the safety of CYT-108, our experimental recombinant protease inhibitor drug candidate for osteoarthritis, in a population of patients suffering from osteoarthritis of the knee. The main questions this study aims to answer are: 1. are two doses of CYT-108, delivered 12 weeks apart, safe when injected directly into the joint? 2. does administration of CYT-108 result in a reduction in pain, stiffness, and improvement in daily physical function? Participants will either receive a placebo (Phosphate Buffer Saline, PBS) or CYT-108, and will be asked to report their pain/stiffness at weeks 1, 4, 8, 12, 16, and 26 (in a physician's office) after the initial injection, using a questionnaire to be provided by the physician. In addition to reporting the magnitude of pain, participants will also be asked about the onset of pain reduction. Researchers will compare the pain/stiffness scores between the CYT-108-treated to placebo-treated groups along the 26 week duration of the study. Participants will also receive blood draws along the course of the study, and researchers will analyze this blood for the presence of cartilage degradation product in attempt to identify "disease modification" (i.e., a reduction in cartilage degradation) in response to CYT-108 treatment.
Conditions
- Osteoarthritis, Knee
- Osteoarthritis
Interventions
CYT-108, a recombinant protease inhibitorBiological
CYT-108 is a recombinant alpha-2-macroglobulin (A2M) variant engineered with increased potency against A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) substrates while possessing strong activity against Matrix Metalloproteinases (MMPs) and serine proteases. This A2M variant was engineered with amino acid modifications to the "bait" region (i.e., protease-binding region) of the A2M protein to make the variant at least two fold more effective in inhibiting ADAMTSs compared to wt-A2M without affecting its inhibitory activity toward other proteases (see Investigator Brochure). CYT-108 is not expected to cure osteoarthritis (OA), but it is expected to be the first treatment to slow disease progression by inhibiting cartilage breakdown, resulting in clinically significant outcomes such as pain reduction and improvement in mobility. This hypothesis is supported by our preliminary findings in multiple safety and efficacy studies conducted in rat and canine models of OA.
Phosphate Buffered Saline (PBS)Other
Phosphate Buffered Saline (PBS)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: Day 0; Weeks 1, 4, 8, 12, 16, 26
- Blood PressureTime frame: Day 0; Weeks 1, 4, 8, 12, 16, 26
- Heart RateTime frame: Day 0; Weeks 1, 4, 8, 12, 16, 26
- Respiratory RateTime frame: Day 0; Weeks 1, 4, 8, 12, 16, 26
- Body TemperatureTime frame: Day 0; Weeks 1, 4, 8, 12, 16, 26
- Titer of Human Anti-Drug AntibodyTime frame: Day 0; Weeks 1, 4, 8, 12, 16, 26
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Sunshine Coast Clinical Trials
Sunshine Coast, Birtinya QLD, Australia
Novatrials
Kotara, New South Wales, Australia
Emeritus Research
Camberwell, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.